ANALYSIS: Should Innovators Be Pursuing Biosimilars?
This article was originally published in PharmAsia News
Executive Summary
Patent expiries, pricing pressures and the emergence of approval pathways in countries like China and Brazil mean that biosimilars offer a substantial global opportunity. There are many good reasons why originator companies should consider investing in this market segment, say Anna Buscall and Christopher Stothers.